Key result
Eptifibatide during STEMI PCI linked to profound thrombocytopenia and subsequent acute stent thrombosis.
Case Report (n=1)
This is the first reported case associating acute stent thrombosis with eptifibatide-induced profound thrombocytopenia in a patient undergoing primary PCI.
Raises vigilance for eptifibatide-related stent thrombosis in STEMI PCI; first case leaves causality and incidence open.
BACKGROUND: Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). CASE: We describe a case of a 62-year-old female patient admitted with acute ST-elevation myocardial infarction (STEMI) treated by primary coronary intervention (primary PCI) with a drug-eluting stent placement. She developed profound thrombocytopenia within 8 hours of first administration of eptifibatide and subsequent acute stent thrombosis next day. Other causes of thrombocytopenia were excluded and intravascular ultrasound (IVUS) showed good stent expansion and opposition to the coronary wall. Platelet count gradually returned to normal after discontinuation of eptifibatide. CONCLUSION: Although Eptifibatide has been associated with the development of thrombocytopenia, to the best of our knowledge, this is the first case report in the medical literature that associates acute stent thrombosis and eptifibatide-induced thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Aljundi et al. (2020) conducted a case report in ST-elevation myocardial infarction (STEMI) (n=1). Eptifibatide was evaluated on Development of profound thrombocytopenia and acute stent thrombosis. Eptifibatide administration during primary PCI for STEMI was associated with profound thrombocytopenia within 8 hours and subsequent acute stent thrombosis the next day in a 62-year-old female.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: